The AUR87A study found that urine collected biomarkers could accurately predict recurrence of kidney cancer in post-surgery ...

Fruzaqla given in combination with sintilimab slowed progression in the second line for those with locally advanced or metastatic renal cell carcinoma.

Among patients with renal cell carcinoma, those with larger tumors may yield the most benefit from SBRT compared with other ...

Excess weight in midlife is a known risk factor for kidney cancer, but new research indicates that weight patterns throughout ...

Count Me In, a patient-partnered research initiative led by the Broad Institute of MIT and Harvard and Dana-Farber Cancer ...

An expert discusses how third line (3L) systemic therapy for metastatic renal cell carcinoma (mRCC) is guided by prior ...

Hutchmed China, alongside Innovent Biologics, announced on Wednesday that the FRUSICA-2 phase two and three clinical trial ...

A simple urine test could accurately show the recurrence of kidney cancer at an early stage, potentially sparing patients invasive scans and enabling faster access to treatment, new research has shown ...

The combination of sintilimab and fruquintinib received conditional approval from China’s National Medical Products Administration (NMPA) for the treatment of patients with advanced endometrial cancer ...

which evaluated sintilimab in combination with fruquintinib as second-line treatment for locally advanced or metastatic renal cell carcinoma (RCC) in China, has met its primary endpoint of ...

Count Me In, a patient-partnered research initiative led by Dana-Farber Cancer Institute and the Broad Institute of MIT and ...